TrialInternational journal of clinical oncology2020

Pembrolizumab versus chemotherapy in recurrent, advanced urothelial cancer in Japanese patients: a subgroup analysis of the phase 3 KEYNOTE-045 trial.

Hiroyuki Nishiyama et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.